Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.55 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.53 |
| ▸ | PIK3C2G | O75747 | 2/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.50 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.50 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2283412 | 1.00 | MEN1 (0.61) | MEN1KMT2APIK3CDPIK3CGPIK3CA | |
| SCHEMBL189130 | 0.90 | MEN1 (0.75) | MEN1KMT2APIK3CDPIK3CGPIK3CA | |
| SCHEMBL2300591 | 0.89 | PIK3CD (0.72) | MEN1KMT2APIK3CDPIK3CGPIK3CA | |
| SCHEMBL188933 | 0.88 | PIK3C2B (0.69) | MEN1KMT2APIK3CDPIK3CGPIK3CA | |
| SCHEMBL188796 | 0.88 | PIK3C2B (0.69) | MEN1KMT2APIK3CDPIK3CGPIK3CA | |
| SCHEMBL2279567 | 0.87 | PIK3CD (0.61) | MEN1KMT2APIK3CDPIK3CGPIK3C2B | |
| SCHEMBL2283949 | 0.87 | PIK3CD (0.68) | MEN1KMT2APIK3CDPIK3CGPIK3CA | |
| SCHEMBL2276250 | 0.87 | PIK3CD (0.68) | MEN1KMT2APIK3CDPIK3CGPIK3CA | |
| SCHEMBL2278848 | 0.85 | PIK3CD (0.66) | MEN1KMT2APIK3CDPIK3CGPIK3CA | |
| SCHEMBL2283565 | 0.85 | PIK3CD (0.66) | MEN1KMT2APIK3CDPIK3CGPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207712-A1 | Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use | EXELIXIS, INC. (US) | 2011-08-25 | — | — | US | claimed |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2010-04-08 | — | — | US | claimed |
| EP-2364974-A1 | N-(3-Phenylamino-quinoxalin-2-yl)-benzenesulfonamide derivatives as phosphatidylinositol 3-kinase inhibitors | Exelixis, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | PIK3CA, PIK3CB, PIK3CG | MEN1 3161/4885KMT2A 2013/4885PIK3CD 4/4885 |
| US-20110207712-A1 | Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use | PIK3CA, PIK3CB, PIK3CG | MEN1 3161/4885KMT2A 2013/4885PIK3CD 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.